Company Active LTD

Company profile

Owen Mumford Limited

UK company 01257871, incorporated on 10 May 1976.

HomePage | Owen Mumford

Making a world of difference in medical device design innovation Owen Mumford

Company number
01257871
Incorporated
10 May 1976
Companies House status
Active

Company identity

Founded / incorporated
10 May 1976

Company number 01257871

Verify at Companies House
Legal name
OWEN MUMFORD LIMITED
Company type
Private Limited Company
Region
South East England
Registered address
PRIMSDOWN INDUSTRIAL ESTATE
WORCESTER ROAD
CHIPPING NORTON
ENGLAND
OX7 5XP
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

2 levels 1 ultimate controller Controls 1
1
Company Active LTD
Owen Mumford Limited
CRN 01257871
2
Direct controller Active LTD
3
Ultimate controller
06066556
CRN 06066556

Company events

Reference milestones and recent Companies House filing stream events.

5 events
30 Jun
2027

Accounts due

Accounts Due

Next accounts due date

17 Jun
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

03 Jun
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Sep
2025

Accounts filed

Accounts

Last accounts made up date

10 May
1976

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2020
Funded years
2020, 2025
Age at first award
44 years

Projects

2025 Feasibility Studies Lead participant

Remanufacturing for a Sustainable Future in Combination Injection Devices (ReSCid)

1 Jan 2025 to 30 Jun 2025

Awarded
£29,667
Total cost £29,667

Combination drug devices combine a pharmaceutical drug with an injection device, essential for the efficacy of many drugs, especially novel modalities like biologics and nucleic acids. As these novel drug modalities increase, so does the need for combination devices. To ensure a sustainable future for the pharma industry, targeting this component of their...

2020 Collaborative R&D Lead participant

Design of a Vaccine-specific Autoinjector Device to provide a long-term pandemic solution for the UK

1 Dec 2020 to 30 Nov 2021

Awarded
£355,559
Total cost £444,449

The UK Healthcare system faces an enormous challenge to facilitate the administration of a population-wide immunisation programme against COVID-19\. The widespread nature of the process of vaccination has meant that, until now, there has never been a pharmaco-economic justification that could bear the additional costs of vaccination using a self-administr...

Product types

Collaborative R&D Feasibility Studies